Cited 5 times in
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신상준 | - |
dc.date.accessioned | 2024-01-03T00:31:04Z | - |
dc.date.available | 2024-01-03T00:31:04Z | - |
dc.date.issued | 2023-11 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197278 | - |
dc.description.abstract | Purpose: The MORPHEUS platform was designed to identify early efficacy signals and evaluate the safety of novel immunotherapy combinations across cancer types. The phase Ib/II MORPHEUS-UC trial (NCT03869190) is evaluating atezolizumab plus magrolimab, niraparib, or tocilizumab in platinum-refractory locally advanced or metastatic urothelial carcinoma (mUC). Additional treatment combinations were evaluated and will be reported separately. Patients and methods: Patients had locally advanced or mUC that progressed during or following treatment with a platinum-containing regimen. The primary efficacy endpoint was investigator-assessed objective response rate (ORR). Key secondary endpoints included investigator-assessed progression-free survival (PFS) and overall survival (OS). Safety and exploratory biomarker analyses were also conducted. Results: Seventy-six patients were randomized to receive either atezolizumab plus magrolimab (n = 16), atezolizumab plus niraparib (n = 15), atezolizumab plus tocilizumab (n = 15), or atezolizumab monotherapy (control; n = 30). No additive benefit in ORR, PFS, or OS was seen in the treatment arms versus the control. The best confirmed ORR was 26.7% with atezolizumab plus magrolimab, 6.7% with atezolizumab plus niraparib, 20.0% with atezolizumab plus tocilizumab, and 27.6% with atezolizumab monotherapy. Overall, the treatment combinations were tolerable, and adverse events were consistent with each agent's known safety profile. Trends were observed for shrinkage of programmed death-ligand 1-positive tumors (atezolizumab, atezolizumab plus magrolimab, atezolizumab plus tocilizumab), inflamed tumors, or tumors with high mutational burden (atezolizumab), and immune excluded tumors (atezolizumab plus magrolimab). Conclusions: The evaluated regimens in MORPHEUS-UC were tolerable. However, response rates for the combinations did not meet the criteria for further development in platinum-experienced locally advanced or mUC. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | American Association for Cancer Research | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Carcinoma, Transitional Cell* / pathology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Platinum / therapeutic use | - |
dc.subject.MESH | Urinary Bladder Neoplasms* | - |
dc.subject.MESH | Urologic Neoplasms* / pathology | - |
dc.title | Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Alexandra Drakaki | - |
dc.contributor.googleauthor | Thomas Powles | - |
dc.contributor.googleauthor | Aristotelis Bamias | - |
dc.contributor.googleauthor | Juan Martin-Liberal | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Terence Friedlander | - |
dc.contributor.googleauthor | Diego Tosi | - |
dc.contributor.googleauthor | Chandler Park | - |
dc.contributor.googleauthor | Carlos Gomez-Roca | - |
dc.contributor.googleauthor | Florence Joly Lobbedez | - |
dc.contributor.googleauthor | Daniel Castellano | - |
dc.contributor.googleauthor | Rafael Morales-Barrera | - |
dc.contributor.googleauthor | Irene Moreno-Candilejo | - |
dc.contributor.googleauthor | Aude Fléchon | - |
dc.contributor.googleauthor | Kobe Yuen | - |
dc.contributor.googleauthor | Deepali Rishipathak | - |
dc.contributor.googleauthor | Kelly DuPree | - |
dc.contributor.googleauthor | Fiona Young | - |
dc.contributor.googleauthor | Francesca Michielin | - |
dc.contributor.googleauthor | Colby S Shemesh | - |
dc.contributor.googleauthor | Elizabeth E Steinberg | - |
dc.contributor.googleauthor | Patrick Williams | - |
dc.contributor.googleauthor | Jae Lyun Lee | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-23-0798 | - |
dc.contributor.localId | A02105 | - |
dc.relation.journalcode | J00564 | - |
dc.identifier.pmid | 37651261 | - |
dc.identifier.url | https://aacrjournals.org/clincancerres/article/29/21/4373/729622/Atezolizumab-plus-Magrolimab-Niraparib-or | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | 신상준 | - |
dc.citation.volume | 29 | - |
dc.citation.number | 21 | - |
dc.citation.startPage | 4373 | - |
dc.citation.endPage | 4384 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, Vol.29(21) : 4373-4384, 2023-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.